Webinar on Hepatobiliary Neoplasia Registry and Biorepository
Join us on Monday, February 11 at 12:00 p.m. eastern (9:00 a.m. pacific) for a presentation by Dr. Lewis R. Roberts from the Mayo Clinic in Rochester, MN on the three main types of studies he is performing regarding cholangiocarcinoma (bile duct cancer). Included will be details on the:
Research Plan: The collected samples will be used for three main types of studies:
1. DNA samples from patients with cholangiocarcinoma will be used for a genome-wide association study to determine the genetic variants that confer risk for cholangiocarcinoma.
2. Serum samples from patients with cholangiocarcinoma will be used to validate new biomarkers for early detection and diagnosis of cholangiocarcinoma.
3. Tissue samples obtained at surgical resection will be implanted into immunodeficient mice to create patient derived xenografts and will also be snap frozen in liquid nitrogen for future comprehensive genome-wide molecular analyses such as is performed by the National Cancer Institutes Cancer Genome Atlas Project (TCGA).
This is one of four research grants funded in 2012 by the Cholangiocarcinoma Foundation. Thank you to everyone who supports us. We could not do it without you.
More research grant webinars are scheduled for later this month. Check back for more details soon.
February is cholangiocarcinoma awareness month, and The Cholangiocarcnoma Foundation will be leading numerous events in February to help raise awareness of this rare cancer. Events includefundraising for 2013 research grants, awareness drives on Facebook and Twitter, spotlight webinars on research efforts, and much more.
“February gives our community a dedicated month-long opportunity to focus their energy to educate the general public about cholangiocarcinoma (bile duct cancer) and the challenges associated with diagnosis, living with this cancer and finding a cure,” said foundation president, Stacie Lindsey. She added, “Similar to last year’s effort, we’ll be offering engaging and informative activities based on our mission of Collaboration, Understanding, Research and Education to assist with directing our efforts.” To participate or learn more visit the foundation’s web site at: http://www.cholangiocarcinoma.orgRead More
The Cholangiocarcinoma Foundation awarded $184,202 in Grants and Project Funding in 2012. A $40,000 Grant was awarded to the UCSF Hepatobiliary Tissue Bank(CC#124512) which will support the advancing translational Science in Cancers of Biliary Tract through Biorepository of Human Tumor and Blood Specimens. The goal of the HBTB is to advance our understanding of this rare and under-studied tumor type. The immediate goal of the HBTB is to collect high quality frozen cholangiocarcinoma specimens along with paired normal tissue (blood or normal liver) to support the opening of a cholangiocarcinoma cohort with the National Cancer Institute’s the Cancer Genome Atlas (TCGA). Another $40,000 was awarded for Cell Lines and Novel Antibodies at Massachusetts General Hospital. The support will test a novel immunotherapeutic strategy which targets not only differentiated cholangiocarcinoma cells, but all cholangiocarcinoma stem cells. An additional $44,202 was given to the Mayo Clinic for Hepatobiliary Neoplasia Registry and Biorepository. The overall goal is to support the collection of clinical information and samples of blood and tissue from patients with hepatobiliary neoplasia in an IRB approved International Hepatobiliary Neoplasia Registry and Biorepository. Finally, The American Society of Clinical Oncology was awarded $60,000 for its Young Investigator Award. This grant is intended to raise awareness and trigger progress against cholangiocarcinoma, while providing critical early funding for physician-scientists at the beginning of their careers in the field. Providing early career grants helps encourage investigators to focus their career on bile duct cancer.Read More
Dr. Said Almamari from Oxford University in the UK is very interested in collaborating with the Cholangiocarcinoma Foundation. He is currently doing research on Primary Sclerosing Cholangitis (PSC) and Cholangiocarcinoma (CC). Upon the completion of his Study he will return to Yemen, where there are many cases being untreated.